Document 0543
 DOCN  M9610543
 TI    Administration of a nondepleting anti-CD4 monoclonal antibody (W3/25)
       prevents adjuvant arthritis, even upon rechallenge: parallel
       administration of a depleting anti-CD8 monoclonal antibody (OX8) does
       not modify the effect of W3/25.
 DT    9601
 AU    Pelegri C; Paz Morante M; Castellote C; Castell M; Franch A; Unit of
       Physiology, Faculty of Pharmacy, University of Barcelona,; Spain.
 SO    Cell Immunol. 1995 Oct 15;165(2):177-82. Unique Identifier : AIDSLINE
       MED/96021255
 AB    The aim of this study was to determine the effects of the anti-CD4
       monoclonal antibody (mAb) W3/25, found to be nondepleting, on the onset
       of rat adjuvant arthritis (AA), and, in addition, to ascertain whether
       depletion of CD8+ cells during the same period could interfere with
       those effects. Female Wistar rats in which AA had been induced were
       treated with W3/25 and/or OX8 (anti-rat CD8) mAb during the latency
       period of arthritis. W3/25 alone or in combination with OX8 prevented
       the inflammatory process of AA. When the protected groups were
       rechallenged with a second dose of Mycobacterium butyricum no arthritis
       was observed. Protected and nonprotected arthritic animals developed the
       same anti-mycobacteria antibody levels as the arthritic control group.
       This study indicates that a nondepleting anti-CD4 mAb can prevent AA,
       while CD8+ lymphocytes do not appear relevant for the development of AA
       and do not seem to have a regulatory role for CD4+ cells.
 DE    Animal  Antibodies, Bacterial/BLOOD  Antibodies, Monoclonal/*THERAPEUTIC
       USE  Antigens, CD4/*PHYSIOLOGY  Antigens, CD8/*PHYSIOLOGY  Arthritis,
       Adjuvant/IMMUNOLOGY/*PREVENTION & CONTROL  CD4-CD8 Ratio  Female  Mice
       Mycobacterium/IMMUNOLOGY  Rats  Rats, Wistar  Support, Non-U.S. Gov't
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).